{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:52:45Z","timestamp":1777056765034,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":4080,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA-102216"],"award-info":[{"award-number":["CA-102216"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1093\/annonc\/mdn365","type":"journal-article","created":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:13:16Z","timestamp":1211847196000},"page":"1759-1764","source":"Crossref","is-referenced-by-count":38,"title":["Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"J.H.","family":"Mendler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Voci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Marquis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.H.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Liesveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn365_bb0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0015","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn365_bb0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.20020062","article-title":"Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity","volume":"196","author":"Hinz","year":"2002","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdn365_bb0025","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V97.9.2798","article-title":"Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin\/Reed-Sternberg cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn365_bb0030","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V94.9.3129","article-title":"Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells","volume":"94","author":"Emmerich","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn365_bb0035","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdn365_bb0040","first-page":"1145","article-title":"Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines","volume":"9","author":"Ling","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdn365_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdn365_bb0050","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0055","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1056\/NEJMp030092","article-title":"The proteasome\u2014an emerging therapeutic target in cancer","volume":"348","author":"Mitchell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn365_bb0060","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2005-01-0427","article-title":"The fully human anti-CD30 antibody 5F11 activates NF-\u03baB and sensitizes lymphoma cells to bortezomib-induced apoptosis","volume":"106","author":"Boll","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn365_bb0065","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","article-title":"Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer","volume":"54","author":"Noble","year":"1997","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdn365_bb0070","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.11582","article-title":"Gemcitabine added to doxorubicin, bleomycin, and vinblastine (ABVG) for the treatment of de novo Hodgkin's disease (HD): unacceptable acute pulmonary toxicity","volume":"98","author":"Friedberg","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn365_bb0075","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.1999.17.8.2625","article-title":"Gemcitabine is active in relapsed Hodgkin's disease","volume":"17","author":"Lucas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0080","first-page":"926","article-title":"Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients","volume":"85","author":"Zinzani","year":"2000","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdn365_bb0085","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jsre.2001.6194","article-title":"Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome","volume":"100","author":"Bold","year":"2001","journal-title":"J Surg Res"},{"key":"10.1093\/annonc\/mdn365_bb0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-4804(03)00201-4","article-title":"Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer","volume":"113","author":"Fahy","year":"2003","journal-title":"J Surg Res"},{"key":"10.1093\/annonc\/mdn365_bb0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1158\/1535-7163.MCT-05-0290","article-title":"SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone","volume":"5","author":"Chung","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdn365_bb0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1535-7163.279.3.3","article-title":"The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo","volume":"3","author":"Kamat","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdn365_bb0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-004-0811-4","article-title":"Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line","volume":"54","author":"Mortenson","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdn365_bb0115","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.athoracsur.2004.04.029","article-title":"Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis","volume":"78","author":"Denlinger","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1093\/annonc\/mdn365_bb0120","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.22264","article-title":"Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors","volume":"107","author":"Ryan","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn365_bb0125","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0130","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0135","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428190701411458","article-title":"Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206","volume":"48","author":"Blum","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdn365_bb0145","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.10797","article-title":"Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study","volume":"92","author":"Trelle","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdn365_bb0150","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/annonc\/mdi324","article-title":"PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study","volume":"16","author":"Alberts","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn365_bb0155","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341940183X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341940183X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/10\/1759\/661183\/mdn365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:16:41Z","timestamp":1684419401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341940183X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S092375341940183X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn365","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}